Jun 10, 2021 / 07:00PM GMT
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. Welcome back, everyone, and thank you for joining us on Day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. I'm Paul Choi, and I cover the mid-cap biotechnology sector here at the firm. And our next session will be with FibroGen.
Joining us from management is CEO, Enrique Conterno. What we'll do as in prior sessions is we'll turn it over to Enrique for some opening commentary, and then we'll go into Q&A. (Operator Instructions)
But otherwise, with that, we'll turn it over to Enrique.
Enrique A. Conterno - FibroGen, Inc. - CEO & Director
Thank you, Paul, and thank you for the invitation. A few comments on FibroGen. We are, of course, excited about the -- having the AdCom with the -- here in the U.S., and the preparations are going well. The AdCom is July 15. Also waiting for the regulatory decision in Europe. That's another important milestone for us.
And of course, I think, continue to be very bullish about our performance in
FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers